Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 4, 2005, Pages 371-378

  Guadagnolo, Beverly Ashleigh ^a,e   Haddad, Robert I ^b   Posner, Marshall R ^b   Weeks, Linda ^b   Wirth, Lori J ^b   Norris, Charles M ^c   Sullivan, Christopher A ^c   Goguen, Laura ^c   Busse, Paul M ^d   Tishler, Roy ^d  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Department of Radiation Oncology ^*  (United States)

Author keywords

Induction chemotherapy; Larynx cancer; Organ preservation; Radiation therapy; Swallowing dysfunction

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DYSPHAGIA; FOLLOW UP; GASTROSTOMY; HUMAN; LARYNGECTOMY; LARYNX CANCER; LYMPH NODE METASTASIS; ORGAN PRESERVATION; RADIATION DOSE FRACTIONATION; REVIEW; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE FRACTIONATION; ESOPHAGEAL STENOSIS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LARYNGEAL NEOPLASMS; LARYNGECTOMY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS;

EID: 23244466821     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000162423.13431.8d     Document Type: Review

References (24)

1. Wolf GT. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
2. Lefebvre J-L, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III Trial. J Natl Cancer Inst. 1996;88:890-899.
3. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-2098.
4. Garden AS. Organ preservation for carcinoma of the larynx and hypopharynx. Hematol Oncol Clin North Am. 2001;15:243-260.
5. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949-955.
6. Lazarus CL, Logemann JA, Pauloski BR, et al. Swallowing disorders in head and neck cancer patients treated with radiotherapy and adjuvant chemotherapy. Laryngoscope. 1996;106:1157-1166.
7. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161-1171.
8. Meleca RJ, Dworkin JP, Kewson DT, et al. Functional outcomes following nonsurgical treatment for advanced-stage laryngeal carcinoma. Laryngoscope. 2003;113:720-728.
9. Colevas AD, Busse P, Norris CM. Induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck. J Clin Oncol. 1998;16:1331-1339.
10. Colevas AD, Norris CM, Tishler RB. A phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999;17:3503-3511.
11. Colevas AD, Norris CM, Tishler RB. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol. 2002;25:153-159.
12. Haddad R, Colevas AD, Tishler RB, et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2003;97:412-418.
13. Tishler RB, Norris CM, Colevas AD, et al. A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer. 2002;95:1472-1481.
14. Posner MR, Glisson B, Frenette G. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19:1096-1104.
15. Tishler RB, Haddad R, Norris CM, et al. Phase I/II trial of docetaxel and concomitant boost radiation therapy for patients with squamous cell carcinoma of the head and neck following induction chemotherapy. Proc Am Soc Clin Oncol. 2003;22:506.
16. Haddad R, Tishler RB, Norris CM, et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based chemotherapy for head and neck cancer and the case for sequential, combined modality treatment. Oncologist. 2003;8:35-44.
17. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000;88:876-883.
18. Carrara-de Angelis E, Feher O, Barros APB, et al. Voice and swallowing in patients enrolled in a larynx preservation trial. Arch Otolaryngol Head Neck Surg. 2003;129:733-738.
19. Staton J, Robbins KT, Newman L, et al. Factors predictive of poor functional outcome after chemoradiation for advanced laryngeal cancer. Otolaryngol Head Neck Surg. 2002;127:43-47.
20. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34:224-228.
21. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare the hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of the RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7-16.
22. Keum KC, Kim GE, Suh CO, et al. Role of definitive radiation therapy for larynx preservation in patient with advanced laryngeal cancer. J Otolaryngol. 1999;28:245-251.
23. Terrell JE, Fisher SG, Wolf GT. Long-term quality of life after treatment of laryngeal cancer. Arch Otolaryngol Head Neck Surg. 1998;124:964-971.
24. Monnerat C, Faivre S, Temam S, et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol. 2002;13:995-1006.